NCT04003207View on ClinicalTrials.gov

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

June 5, 2020

Study Completion Date

June 5, 2020

Conditions
Phelan McDermid Syndrome
Interventions
DRUG

Recombinant human Growth hormone

Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.

Trial Locations (1)

10029

Seaver Autism Center, New York

All Listed Sponsors
lead

Swathi Sethuram

OTHER

NCT04003207 - Growth Hormone Treatment in Children With Phelan McDermid Syndrome | Biotech Hunter | Biotech Hunter